89bio Aktie
WKN DE: A2PUP8 / ISIN: US2825591033
08.08.2025 04:38:16
|
89bio (ETNB) Q2 R&D Jumps 131%
89bio (NASDAQ:ETNB), a clinical-stage biotech focused on metabolic and liver diseases, released its second quarter 2025 results on August 7, 2025. The company posted GAAP earnings per share of $(0.71), missing the consensus estimate of $(0.50) and falling below $(0.48) in Q2 2024. There was no revenue, as expected for a development-stage company. Expenses (GAAP) increased sharply, especially in research and development, reflecting both the ramp-up of late-stage clinical programs and a significant one-time payment for commercial manufacturing infrastructure. Management judged the quarter as broadly in line with its strategic focus on advancing pegozafermin, its lead candidate, but highlighted that the company remains in a clinical stage with no commercial revenue yet. Source: Analyst estimates for the quarter provided by FactSet. 89bio develops new medicines for metabolic and liver diseases. Its lead asset, pegozafermin, is a drug candidate designed to treat serious conditions like metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and severe hypertriglyceridemia (SHTG).Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu 89bio Inc Registered Shsmehr Nachrichten
Analysen zu 89bio Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
89bio Inc Registered Shs | 14,87 | -0,60% |
|
Q2 Holdings Inc | 71,00 | 1,43% |
|